OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
orbimed.com
Update Information

More venture news

Ryft
17 Sept 2026
Ryft unlocks £20m Series B led by Gresham House Ventures to serve marketplaces and platforms with multi-party payments architecture
Series BFintech
Breedr
26 Aug 2026
Breedr unlocks £20m Series B led by Partech to digitalise the global cattle supply chain
Series BAgriculture
Olix
3 Aug 2026
OLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production
Series BDeep Tech

OrbiMed

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Ryft unlocks £20m Series B led by Gresham House Ventures to serve marketplaces and platforms with multi-party payments architecture

Breedr unlocks £20m Series B led by Partech to digitalise the global cattle supply chain

OLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production